Published
GLP-1 / GIP / Glucagon Triple Agonists — Research Protocols for Retatrutide
Review of the published research protocols for Retatrutide and related triple GIP/GLP-1/glucagon agonists, including dosing escalation, side-effect management and comparative context.
Retatrutide is the most prominent member of a new pharmaceutical class — triple agonists at the GLP-1, GIP and glucagon receptors. In published Phase II human research (SURMOUNT-equivalent design) Retatrutide produced ~24% mean body weight reduction at 48 weeks, the largest peptide-driven weight change documented in the human peptide literature to date.
This article reviews the published research-protocol design and how it informs the dosing structure used on the Tirzepatide + Retatrutide + AOD-9604 metabolic stack page.
Mechanism — why three receptors
The three receptor families address complementary metabolic levers:
- GLP-1 receptor agonism — slows gastric emptying, suppresses appetite via vagal and hypothalamic signalling, augments glucose-dependent insulin secretion.
- GIP receptor agonism — augments postprandial insulin release; in animal models also modulates adipocyte lipid handling. The role of GIP agonism in obesity research is the subject of ongoing literature — initially controversial (GIP was historically associated with obesity), now understood through the lens of biased-agonism literature.
- Glucagon receptor agonism — increases hepatic glucose output and energy expenditure. This third arm is what distinguishes Retatrutide from Tirzepatide and is the proposed mechanism behind the additional weight loss observed.
Dosing escalation in the published protocol
The Phase II Retatrutide trials used a step-up titration schedule designed to manage gastrointestinal tolerance:
| Weeks | Dose (research subjects) |
|---|---|
| 1–2 | 2 mg weekly |
| 3–4 | 4 mg weekly |
| 5–6 | 6 mg weekly |
| 7+ | Maintained at 6 mg or escalated to 8–12 mg in higher-dose arms |
This escalation pattern informs the dosing column in our metabolic stack page. Aggressive escalation produces dose-limiting nausea; the slow escalation produces equivalent outcomes by week 24 with significantly better tolerability.
Comparative context — Retatrutide vs Tirzepatide
- Tirzepatide: dual GIP/GLP-1; SURMOUNT-1 documented ~21% weight reduction at 72 weeks (15 mg arm).
- Retatrutide: triple GIP/GLP-1/glucagon; Phase II ~24% at 48 weeks (12 mg arm).
The two compounds have not been compared head-to-head in published trials. Research protocols typically sequence them — Tirzepatide first, transition to Retatrutide — rather than co-administering them.
Pairing with AOD-9604
The rationale for combining incretin agonists with AOD-9604 (the GH C-terminal lipolytic fragment) rests on two observations:
- AOD-9604 acts directly on adipocyte β3 receptor lipolysis — a mechanism distinct from incretin appetite suppression
- AOD-9604 does not activate GH receptor and does not produce IGF-1 elevations — it does not compete with the incretin pharmacology
This combination is research-only; no human clinical trial has examined the three-peptide stack together.
Side-effect management in research protocols
The published GI side-effect profile of triple agonists is dose-dependent and predominantly nausea, delayed gastric emptying, and constipation. Research protocols mitigate this through:
- Slow dose escalation (the schedule above)
- Hydration emphasis
- Smaller, more frequent meal patterns in research subjects
- Pre-treatment screening for pancreatitis history (boxed warning class effect)
For protocol detail and dosing tables, see the full Tirzepatide + Retatrutide + AOD-9604 metabolic research stack page.